Tag Archives: rcpt

Celgene To Buy Receptos For $7.2 Billion; Profit Soars

Celgene (CELG) late Tuesday said it will pay $232 a share in cash for Receptos (RCPT), and announced strong Q2 earnings and sales figures. The biotech giant said the deal “significantly enhances Celgene’s inflammation & immunology portfolio,” Receptos, which is developing treatments for multiple sclerosis and ulcerative-colitis, rose 10.2% to 228.25 in after-hours action after being halted on the deal announcement. The stock had closed up 5.1% to

Receptos MS Drug Succeeds Against Ulcerative Colitis

Biotech Receptos (RCPT) reported positive midstage trial results for its lead drug candidate for ulcerative colitis Thursday, sending the stock up as much as 7% in early trading. Receptos said that the phase-two study, called Touchstone, met all six of its primary endpoints for improving the chronic bowel disease after 32 weeks of maintenance with ozanimod, formerly known as RPC1063. Ozanimod first made a splash last September with its midstage

Receptos Soars After Lead Drug Racks Up Another Win

Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late Monday that its drug RPC1063 had proven significantly better than a placebo in patients with ulcerative colitis (UC), a disease involving inflammation and ulcers in the colon. At the end of eight weeks,